NCT06167707View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions
Heart FailureFluid Overload
Interventions
DRUG

SCP-111

Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose

DRUG

Furosemide USP

Furosemide injection, USP 10 mg/mL, 40 mg IV over 2 minutes followed by 40 mg 2 hours later

Trial Locations (1)

33618

Elixia EPCT, LLC, Tampa

All Listed Sponsors
lead

scPharmaceuticals, Inc.

INDUSTRY

NCT06167707 - Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers | Biotech Hunter | Biotech Hunter